Your search for oral corticosteroids returned 63 results

Acton announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for its new asthma product, Aerospan (flunisolide HFA, 80 mcg) Inhalation Aerosol.

The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Ten days of treatment linked to increase in peak thrombin, velocity index, PAI-1, and vWF

The FDA has approved Promacta tablets (eltrombopag, from GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have been unresponsive to corticosteroids, immunoglobulins or splenectomy.

Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.

Case report describes 69-year-old who developed EM after seven days of triple antibiotic therapy

Control of inflammation not superior with mycophenolate mofetil versus methotrexate

Management is generally in a stepwise manner, including moisturizers and avoiding triggers

Findings may help with decision-making in this high-risk patient population.

Pediatric allergic contact dermatitis (ACD) to methylisothiazolinone (MI) may be increasing and should be considered in cases with a history of wet wipe use.